R T Davey

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies
    Richard T Davey
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS ONE 8:e57121. 2013
  2. pmc HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
    R T Davey
    National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 96:15109-14. 1999
  3. doi request reprint Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy
    Richard T Davey
    National Institutes of Health, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:89-100. 2008
  4. ncbi request reprint Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
    R T Davey
    National Institutes of Health, Bethesda, MD 20892 1880, USA
    JAMA 284:183-9. 2000
  5. ncbi request reprint Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
    J A Kovacs
    Critical Care Medicine Department, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1662, USA
    J Infect Dis 182:1063-9. 2000
  6. ncbi request reprint Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 5:651-5. 1999
  7. ncbi request reprint Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
    H Imamichi
    Science Applications International Corporation Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Bethesda, Maryland, USA
    J Infect Dis 183:36-50. 2001
  8. pmc Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV
    J A Kovacs
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 194:1731-41. 2001
  9. ncbi request reprint CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness
    M Dybul
    Laboratory of Immunoregulation and Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Warren Magneson Clinical Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 165:1685-91. 2000
  10. ncbi request reprint Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
    J A Kovacs
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, USA
    Eur J Immunol 31:1351-60. 2001

Detail Information

Publications65

  1. pmc The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies
    Richard T Davey
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS ONE 8:e57121. 2013
    ..To assess predictors of disease progression among patients with influenza A(H1N1)pdm09 infection, 25 inflammatory biomarkers measured at enrollment were analyzed in two international observational cohort studies...
  2. pmc HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
    R T Davey
    National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 96:15109-14. 1999
    ..Virologic relapse occurs rapidly in patients who discontinue suppressive drug therapy, even in patients with a markedly diminished pool of resting, latently infected CD4(+) T cells...
  3. doi request reprint Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy
    Richard T Davey
    National Institutes of Health, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:89-100. 2008
    ..Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary...
  4. ncbi request reprint Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
    R T Davey
    National Institutes of Health, Bethesda, MD 20892 1880, USA
    JAMA 284:183-9. 2000
    ....
  5. ncbi request reprint Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
    J A Kovacs
    Critical Care Medicine Department, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1662, USA
    J Infect Dis 182:1063-9. 2000
    ..Thus, intermittent IL-2 does not result in sustained increases in either plasma or tissue levels of HIV and does not result in sustained expression of a previously silent quasi species...
  6. ncbi request reprint Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 5:651-5. 1999
    ..These results indicate that the intermittent administration of IL-2 with continuous HAART may lead to a substantial reduction in the pool of resting CD4+ T cells that contain replication-competent HIV...
  7. ncbi request reprint Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
    H Imamichi
    Science Applications International Corporation Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Bethesda, Maryland, USA
    J Infect Dis 183:36-50. 2001
    ....
  8. pmc Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV
    J A Kovacs
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 194:1731-41. 2001
    ..01). These findings demonstrate that HIV does not impair CD4 T cell production but does increase CD4 and CD8 lymphocyte proliferation and death by inducing entry into a rapidly proliferating subpopulation of cells...
  9. ncbi request reprint CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness
    M Dybul
    Laboratory of Immunoregulation and Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Warren Magneson Clinical Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 165:1685-91. 2000
    ..They also indicate the potential for CD40LT and IL-12 as immune-based therapies for HIV infection...
  10. ncbi request reprint Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
    J A Kovacs
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, USA
    Eur J Immunol 31:1351-60. 2001
    ....
  11. pmc Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
    R T Davey
    National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 40:1657-64. 1996
    ..Combination therapy with DLV and nucleoside analogs appears promising, with the three-drug combination appearing to be more potent that either two-drug combinations or monotherapy...
  12. ncbi request reprint Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection
    S C Piscitelli
    Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Pharmacol Ther 64:492-8. 1998
    ..99 for the plot of observed versus fitted concentrations. The time-dependent increase in IL-2 clearance, likely receptor-mediated, was well described with use of an indirect-effects pharmacokinetic-pharmacodynamic model...
  13. doi request reprint Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial
    Brian O Porter
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20982, USA
    AIDS 23:203-12. 2009
    ..To evaluate whether interleukin (IL)-2 in patients with chronic HIV infection can maintain CD4 T cell counts during 6 months of HAART interruption...
  14. pmc Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters
    M Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:15161-6. 2001
    ..In addition, there was a decrease in serum cholesterol and triglyceride levels. Intermittent therapy may be an important strategy to reduce cost and toxicity for HIV-infected individuals...
  15. ncbi request reprint CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients
    I Sereti
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD 20892, USA
    AIDS 15:1765-75. 2001
    ..These data suggest that the CD4 expansions seen in the context of intermittent IL-2 therapy are the net result of increases in both cell proliferation and cell death...
  16. pmc Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load
    John C Tilton
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1876, Bethesda, MD 20892 1876, USA
    J Virol 81:2713-25. 2007
    ..In addition, defects in function and phenotype of HIV-specific CD4+ T cells are not readily discernible in the context of antiretroviral therapy but rather are similar to responses to other viruses...
  17. pmc Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels
    Brian O Porter
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    AIDS 23:2015-9. 2009
    ..To determine the effects of interleukin (IL)-2 treatment on inflammatory and thrombotic biomarkers in chronically HIV-infected adults receiving antiretroviral therapy...
  18. pmc Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection
    M A Polis
    National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland 20982 1880, USA
    Antimicrob Agents Chemother 41:1709-14. 1997
    ..Drug interactions should be carefully evaluated in persons with advanced human immunodeficiency virus infection who are receiving multiple pharmacologic agents...
  19. ncbi request reprint Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
    S M Whitcup
    The Clinical Branch, National Eye Institute, National Institutes of Health, Bethesda, MD 20892 1863, USA
    JAMA 282:1633-7. 1999
    ..Persons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required lifelong anti-CMV therapy to prevent the progression of retinal disease and subsequent loss of vision...
  20. ncbi request reprint Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients
    S C Piscitelli
    Department of Pharmacy, Warren G Magnuson Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 16:754-9. 1996
    ..To assess the pharmacokinetics and pharmacodynamics of subcutaneously administered interleukin-2 (IL-2) in patients infected with the human immunodeficiency virus (HIV)...
  21. ncbi request reprint Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 6:757-61. 2000
    ....
  22. ncbi request reprint Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion
    K D Miller
    Critical Care Medicine Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Immunol 99:30-42. 2001
    ....
  23. ncbi request reprint Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 20:701-10. 2006
    ..Understanding the selection and decay of drug-resistant HIV-1 variants is important for designing optimal antiretroviral therapy...
  24. ncbi request reprint Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells
    Irini Sereti
    Clinical and Molecular Retrovirology Section, Labotratory of Immunoregulation, National Institute of Allergy and Infectious Diseases NIH, Building 10, Room 11S 231, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 100:2159-67. 2002
    ..Thus, intermittent administration of IL-2 in HIV(+) patients leads to preferential expansion of a unique subset of CD4(+) T cells that may represent a critical population in T-cell homeostasis...
  25. pmc B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells
    S Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Exp Med 192:637-46. 2000
    ..Furthermore, B cells possess the added capability of circulating in peripheral blood and migrating through tissues where they can potentially interact with and pass virus to T cells...
  26. ncbi request reprint Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen
    Michael A Polis
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U S Department of Health and Human Services, Bethesda, Maryland 20892, USA
    AIDS 17:1167-72. 2003
    ..To determine the longitudinal response of HIV in the cerebrospinal fluid (CSF) to highly active antiretroviral therapy (HAART) and to investigate the levels of indinavir penetrating into the CSF...
  27. ncbi request reprint Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection
    Claire E Farel
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:3282-6. 2004
    ..These observations may contribute to patients' acceptance of subcutaneous IL-2 as a favorable long-term treatment strategy...
  28. ncbi request reprint Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients
    Chris E Keh
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS 20:361-9. 2006
    ..IL-2 is under evaluation in antiretroviral therapy (ART) interruption studies, but it is unclear how the emergence of viremia may affect CD4 expansions...
  29. pmc Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2
    Christiana Iyasere
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1876, USA
    J Virol 77:10900-9. 2003
    ..These results also suggest that relatively high frequencies of HIV-specific CD4(+) T cells persist in the peripheral blood during viremia, are not replicatively senescent, and proliferate when IL-2 is provided exogenously...
  30. pmc Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness
    Prasanna Jagannathan
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1876, USA
    J Virol 83:2728-42. 2009
    ..They also suggest that poor responsiveness to IL-2 is a property of HIV-specific CD8(+) T cells of progressors that is not shared with responses to other viruses over which immunologic control is maintained...
  31. pmc Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy
    Stephen A Migueles
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1876, USA
    J Virol 83:11876-89. 2009
    ..Taken together, these data suggest that there are selective qualitative abnormalities within the HIV-specific CD8+ T-cell compartment that persist under conditions of low levels of antigen...
  32. pmc A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients
    S C Piscitelli
    Department of Pharmacy, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1196, USA
    Antimicrob Agents Chemother 43:647-50. 1999
    ..Side effects were minor throughout the 3-month study period. The tolerability of stavudine, combined with its lack of drug interactions, makes it an attractive agent for use as part of a combination regimen...
  33. ncbi request reprint Evidence for increased T cell turnover and decreased thymic output in HIV infection
    D C Douek
    Vaccine Research Center, Clinical and Molecular Retrovirology Section, National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 167:6663-8. 2001
    ....
  34. ncbi request reprint BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro
    Lynn Matthews
    Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Immunol 113:248-55. 2004
    ..These data suggest that BAY 50-4798 can induce proliferation of unstimulated T cells but loss of T cell selectivity and induction of pro-inflammatory cytokines occur at concentrations exerting the highest biologic activity...
  35. pmc Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 43:406-13. 2005
    ..In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis...
  36. pmc Interferon-alpha produces significant decreases in HIV load
    Jorge A Tavel
    Division of Clinical Research, National Institutes of Health, Bethesda, Maryland, USA
    J Interferon Cytokine Res 30:461-4. 2010
    ..Since treatment with IFN-alpha produces significant decreases in HIV load, additional studies of IFN-alpha as part of a combination regimen are warranted...
  37. pmc Triage and management of accidental laboratory exposures to biosafety level-3 and -4 agents
    Peter Jahrling
    Integrated Research Facility, National Institute of Allergy and Infectious Diseases, Frederick, Maryland 21702, USA
    Biosecur Bioterror 7:135-43. 2009
    ..Instead, laboratory workers accidentally exposed to pathogens should be cared for in hospital isolation suites staffed by highly trained professionals following strict infection control procedures...
  38. ncbi request reprint Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection
    April E Powers
    Nursing and Patient Care Services, National Institutes of Health, Bethesda, Maryland, USA
    AIDS 20:837-45. 2006
    ..To examine the effect of repeated, long-cycle structured intermittent versus continuous HAART on health-related quality of life (HRQL) and symptom distress in patients with chronic HIV infection and plasma HIV RNA of less than 50 copies/ml...
  39. pmc The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients
    Sarah W Read
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Acquir Immune Defic Syndr 56:340-3. 2011
    ..Although IL-2 administration leads to expansion of peripheral blood CD4+ T cells, there is no alteration in the proportion or activation of CD4+ T cells in the gut mucosa...
  40. pmc ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
    Frank Maldarelli
    HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America
    PLoS Pathog 3:e46. 2007
    ..These data suggest that the persistent viremia on current antiretroviral therapy is derived, at least in part, from long-lived cells that are infected prior to initiation of therapy...
  41. ncbi request reprint CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation
    Irini Sereti
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 196:677-83. 2007
    ..Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-infected patients leads to CD4(+) T cell expansions. The factors potentially affecting these expansions were investigated in the present study...
  42. pmc CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients
    Sarah W Read
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
    J Infect Dis 198:843-50. 2008
    ..Thus, an increase in the survival of CD4 T cells appears to be the critical mechanism leading to sustained increases in the CD4 cell counts of HIV-infected patients receiving intermittent IL-2 therapy...
  43. pmc Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions
    Scott R Penzak
    Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Clinical Center Pharmacy Department, Bldg 10, Room 1N 257, Bethesda, MD 20892, USA
    J Clin Pharmacol 48:671-80. 2008
    ....
  44. pmc Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:3229-37. 2003
    ..In addition, the data suggest that there may be multiple compartments contributing to the rebound of plasma viremia and to viral diversity from cycle to cycle of intermittent therapy...
  45. ncbi request reprint Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:388-96. 2003
    ..There was no clear autoimmunization effect by immunologic or virologic parameters. There was no benefit to long-cycle SIT versus continuous HAART with regard to certain toxicity, immunologic, or virologic parameters...
  46. ncbi request reprint A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus
    Jorge A Tavel
    Office of the Clinical Director, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, US
    J Infect Dis 188:531-6. 2003
    ....
  47. ncbi request reprint Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 185:61-8. 2002
    ..Thus, although intermittent IL-2 plus HAART quantitatively increased CD4+ T cells, this increase was not selective for HIV-specific CD4+ or CD8+ T cell responses in recently infected persons...
  48. pmc Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients
    Joseph A Kovacs
    Critical Care Medicine Department, Warren G Magnuson Clinical Center, NIH, Bethesda, Maryland, USA
    J Clin Invest 115:2139-48. 2005
    ....
  49. ncbi request reprint IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation
    Irini Sereti
    Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 104:775-80. 2004
    ..These data suggest that decreased T-cell proliferation is central in the CD4+ T-cell expansions induced by IL-2...
  50. ncbi request reprint A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Infect Dis 189:1974-82. 2004
    ..Adherence to such a regimen may be problematic for certain patients...
  51. pmc In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients
    Irini Sereti
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    J Clin Invest 115:1839-47. 2005
    ..These CD4CD25 cytokine-expanded naive cells, distinct from antigen-triggered cells and Tregs, play a role in the maintenance of a state of low turnover and sustained expansion of the CD4 T cell pool...
  52. pmc High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation
    A C McNeil
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:13878-83. 2001
    ....
  53. pmc CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32
    O J Cohen
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 1876, USA
    J Virol 72:6215-7. 1998
    ..Polymorphisms in the CXCR4 and CCR5 coding sequences other than CCR5-Delta32 do not appear to play a dominant mechanistic role in nonprogression among HIV-infected individuals...
  54. doi request reprint Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection
    K J Cortez
    Division of Human Tissues, Office of Cell Therapy and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA
    HIV Clin Trials 14:149-59. 2013
    ..We investigated the role of baseline CD4+ T-cell counts as a predictor of HBV response to adefovir (ADV) therapy in chronic HBV with and without HIV coinfection...
  55. pmc Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro
    John C Tilton
    LIR, NIAID, NIH, Bldg 10, Rm 11B 09, 10 Center Dr, MSC 1876, Bethesda, MD 20892 1876, USA
    J Virol 82:3997-4006. 2008
    ..Rather, diminished function in vitro is likely a consequence of prior activation via type I interferons or HIV virions in vivo...
  56. pmc Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors
    Dimitrios I Zonios
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:287-94. 2008
    ..CD8 T lymphocytopenia (< 180/mm(3)) and the degree of CD4 T cell activation (measured by HLA-DR expression) at presentation were associated with adverse outcome (opportunistic infection-related death; P = .003 and .02, respectively)...
  57. ncbi request reprint Acute hepatitis caused by a novel strain of hepatitis E virus most closely related to United States strains
    Y Kabrane-Lazizi
    Hepatitis Viruses and Molecular Hepatitis Sections, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Gen Virol 82:1687-93. 2001
    ....
  58. ncbi request reprint High prevalence of osteonecrosis of the femoral head in HIV-infected adults
    Kirk D Miller
    Critical Care Medicine Department, Clinical Center, Building 10, Room 7D43, MSC1662, National Institutes of Health, Bethesda, MD 20892 1662, USA
    Ann Intern Med 137:17-25. 2002
    ..The diagnosis of symptomatic osteonecrosis of the hip in two of the authors' patients, together with reports from community physicians, raised a concern that the prevalence of osteonecrosis is increasing...
  59. ncbi request reprint Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059
    Donald I Abrams
    San Francisco General Hospital, University of California at San Francisco, San Francisco, California 94110, USA
    J Acquir Immune Defic Syndr 29:221-31. 2002
    ..0001). No unanticipated adverse experiences were seen in this trial, to our knowledge the largest randomized evaluation of rIL-2 treatment conducted to date...
  60. ncbi request reprint Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects
    Sarah M Robertson
    Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, New Hampshire Ave, Silver Spring, MD 20901, USA
    Curr Med Res Opin 24:591-9. 2008
    ..Secondary objectives were to compare ritonavir exposure pre- and post-GBE, and assess the effect of GBE on single doses of probe drugs midazolam and fexofenadine...
  61. pmc Determination of the underlying cause of death in three multicenter international HIV clinical trials
    Alan R Lifson
    University of Minnesota, Minneapolis, Minnesota 55454 1015, USA
    HIV Clin Trials 9:177-85. 2008
    ..Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials...
  62. ncbi request reprint CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies
    Roberto C Arduino
    The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Clin Infect Dis 39:115-22. 2004
    ..To more precisely quantitate the effect on CD4 cell response of 3 different doses of scIL-2 that were administered twice daily for 5 days every 8 weeks, the results of these 3 trials were pooled in a meta-analysis...
  63. ncbi request reprint Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials
    Alan R Lifson
    Department of Epidemiology and Community Health, University of Minnesota, 1300 South Second Street, Minneapolis, MN 55454, USA
    HIV Clin Trials 7:125-41. 2006
    ..The processes for reporting and review of progression of HIV disease clinical endpoints are described for two large phase III international clinical trials...
  64. ncbi request reprint Graves' disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection
    Camilo Jimenez
    Joint Endocrinology, Diabetes and Metabolism Fellowship at Baylor College of Medicine The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Thyroid 14:1097-102. 2004
    ..From a practical standpoint, we propose that patients who have received or are receiving treatment with IL-2 who show signs of hyperthyroidism need to be carefully evaluated for GD...
  65. pmc Pharmacokinetics and tolerability of oseltamivir combined with probenecid
    Mark Holodniy
    US Department of Veterans Affairs, Office of Public Health and Environmental Hazards, Washington, DC, USA
    Antimicrob Agents Chemother 52:3013-21. 2008
    ..012). Alternate-day dosing of oseltamivir plus dosing with probenecid four times daily achieved trough oseltamivir carboxylate concentrations adequate for neuraminidase inhibition in vitro, and this combination should be studied further...